Precipio Stock (NASDAQ:PRPO)
Previous Close
$6.15
52W Range
$4.31 - $7.60
50D Avg
$6.47
200D Avg
$6.05
Market Cap
$9.01M
Avg Vol (3M)
$8.57K
Beta
1.42
Div Yield
-
PRPO Company Profile
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
PRPO Performance
Peer Comparison
| Ticker | Company |
|---|---|
| GTH | Genetron Holdings Limited |
| HTGM | HTG Molecular Diagnostics, Inc. |
| APDN | Applied DNA Sciences, Inc. |
| CDNA | CareDx, Inc |
| NTRA | Natera, Inc. |
| GENE | Genetic Technologies Limited |
| XGN | Exagen Inc. |
| LMDX | LumiraDx Limited |
| TWST | Twist Bioscience Corporation |
| SERA | Sera Prognostics, Inc. |
| BNR | Burning Rock Biotech Limited |
| PMD | Psychemedics Corporation |
| CSTL | Castle Biosciences, Inc. |
| OLK | Olink Holding AB (publ) |
| STRR | Star Equity Holdings, Inc. |
| BDSX | Biodesix, Inc. |
| BIAF | bioAffinity Technologies, Inc. |
| MDXH | MDxHealth SA |